Abstract
Off-target binding, batch variability, and multiple productive chains are not just a once in a research blue moon happenstance. They are the direct, common results of industry-wide insufficient antibody characterization that has, is, or will, wreak havoc on your research. Based on their world-leading expertise in proteomics and antibody analysis, Rapid Novor discusses the negative impacts of insufficient Ab characterization and presents a solution that can help researchers confidently proceed with their research.